Edition:
United Kingdom

Aurinia Pharmaceuticals Inc (AUPH.OQ)

AUPH.OQ on NASDAQ Stock Exchange Global Market

4.70USD
8:40pm GMT
Change (% chg)

$-0.06 (-1.26%)
Prev Close
$4.76
Open
$4.74
Day's High
$4.80
Day's Low
$4.65
Volume
204,891
Avg. Vol
174,835
52-wk High
$10.54
52-wk Low
$2.03

Select another date:

Mon, Dec 11 2017

BRIEF-Aurinia Pharmaceuticals Added To The Nasdaq Biotech Index

* AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX Source text for Eikon: Further company coverage:

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights

BRIEF-Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​

* Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​

BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise

* Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​

BRIEF-Aurinia Pharmaceuticals reports Q2 loss per share $‍0.03​

* Aurinia reports second quarter 2017 financial results, and provides operational highlights

BRIEF-Aurinia Pharmaceuticals resolves temporary non-compliance with Nasdaq's audit committee composition rule

* Aurinia resolves temporary non-compliance with Nasdaq's audit committee composition rule Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharma presents voclosporin remission data

* Voclosporin remission data from the phase IIB aura-LV study highlighted at eular 2017

Select another date: